ALIM(Delisted)
Alimera Sciences·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALIM
Alimera Sciences, Inc.
A global pharmaceutical company develops ophthalmic pharmaceuticals that treat diseases affeting the back of the eye, or retina
6310 Town Square, Suite 400, Alpharetta, GA 30005
--
Alimera Sciences, Inc., founded in Delaware on June 4, 2003, is a biopharmaceutical company. The company specializes in the research and development of the commercial application of ophthalmic prescription drugs, and currently focuses on the disease infection of the rear eyeball structure and the retina. The company believes that these diseases are currently not well treated, and this represents a huge market to be developed.
Company Financials
EPS
ALIM has released its 2024 Q2 earnings. EPS was reported at -0.06, versus the expected -0.04, missing expectations. The chart below visualizes how ALIM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALIM has released its 2024 Q2 earnings report, with revenue of 27.00M, reflecting a YoY change of 53.95%, and net profit of -3.31M, showing a YoY change of 66.99%. The Sankey diagram below clearly presents ALIM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
